Poly(ADP-ribose)polymerase-1 (PARP-1) in carcinogenesis: Potential role of PARP inhibitors in cancer treatment

Clinical and Translational Oncology

Volumn 10, Issue 6, 2008, Pages 318-323

  Peralta Leal, Andreína ^a   Rodríguez, María Isabel ^a   Oliver, Francisco Javier ^a  

^a INSTITUTO DE PARASITOLOGÍA Y BIOMEDICINA LÓPEZ NEYRA   (Spain)

Author keywords

Antineoplasic therapy; Carcinogenesis; DNA repair; PARP 1

Indexed keywords

2 (2 METHYL 2 PYRROLIDINYL) 1H BENZIMIDAZOLE 4 CARBOXAMIDE; 3 AMINOBENZAMIDE; 8 HYDROXY 2 METHYL 4(3H) QUINAZOLINONE; AG 014699; APOPTOSIS INDUCING FACTOR; BSI 201; DNA; DNA BINDING PROTEIN; GPI 21016; INO 1001; KU 0058948; KU 59436; NICOTINAMIDE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 2; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; TEMOZOLOMIDE; UNCLASSIFIED DRUG; ZINC FINGER PROTEIN; ANTINEOPLASTIC AGENT; ENZYME INHIBITOR; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PARP1 PROTEIN, HUMAN;

ABSENCE OF SIDE EFFECTS; ADENOSINE DIPHOSPHATE RIBOSYLATION; APOPTOSIS; BREAST CANCER; CANCER CELL CULTURE; CANCER RADIOTHERAPY; CANCER RESEARCH; CARCINOGENESIS; CELL DEATH; CELL KILLING; CELL NUCLEUS; CELL SURVIVAL; CLINICAL TRIAL; DNA DAMAGE; DNA REPAIR; DNA STRAND BREAKAGE; DOWN REGULATION; DRUG EFFICACY; DRUG SAFETY; ENZYME ACTIVATION; ENZYME INHIBITION; GENE EXPRESSION; GENOTOXICITY; GLIOBLASTOMA; HEART INFARCTION; HEMATOLOGIC MALIGNANCY; HOMOLOGOUS RECOMBINATION; HUMAN; MALIGNANT NEOPLASTIC DISEASE; MELANOMA; MITOCHONDRION; OVARY CANCER; PANCREAS ADENOCARCINOMA; PROTEIN TRANSPORT; RADIOSENSITIZATION; REVIEW; UNSPECIFIED SIDE EFFECT; ANIMAL; ENZYMOLOGY; METABOLISM; NEOPLASM;

ANIMALS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; ENZYME INHIBITORS; HUMANS; NEOPLASMS; POLY(ADP-RIBOSE) POLYMERASES;

EID: 51649091688     PISSN: 1699048X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12094-008-0207-8     Document Type: Review

References (38)

1. Chambon P, Weill JD, Mandel P (1963) Nicotinamide mononucleotide activation of new DNA-dependent polyadenylic acid synthesizing nuclear enzyme. Biochem Biophys Res Commun 11:39-43
2. Otto H, Reche PA, Bazan F et al (2005) In silico characterization of the family of PARP-like poly(ADP-ribosyl)transferases (parts). BMC Genomics 6:139
3. de Murcia JM, Niedergang C, Trucco C et al (1997) Requirement of poly(ADP-ribose) polymerase in recovery from DNA damage in mice and in cells. Proc Natl Acad Sci U S A 94:7303-7307
4. Ame JC, Rolli V, Schreiber V et al (1999) PARP-2, a novel mammalian DNA damage-dependent poly(ADP-ribose) polymerase. J Biol Chem 274:17860-17868
5. Menissier de Murcia J, Ricoul M, Tartier L et al (2003) Functional interaction between PARP-1 and PARP-2 in chromosome stability and embryonic development in mouse. Embo J 22:2255-2263
6. D'Amours D, Desnoyers S, D'silva I et al (1999) Poly (ADP-ribosyl)ation reactions in the regulation of nuclear functions. Biochem J 342(Pt 2): 249-268
7. Yu SW, Wang H, Dawson TM et al (2003) Poly(ADP-ribose) polymerase-1 and apoptosis inducing factor in neurotoxicity. Neurobiol Dis 14:303-317
8. D'Amours D, Sallmann FR, Dixit VM et al (2001) Gain-of-function of poly(ADP-ribose) polymerase-1 upon cleavage by apoptotic proteases: implications for apoptosis. J Cell Sci 114:3771-3778
9. Schultz N, Lopez E, Saleh-Gohari N et al (2003) Poly(ADP-ribose) polymerase (PARP-1) has a controlling role in homologous recombination. Nucleic Acids Res 31:4959-4964
10. Hay T, Jenkins H, Sansom OJ et al (2005) Efficient deletion of normal BRCA2-deficient intestinal epithelium by poly(ADP-ribose) polymerase inhibition models potential prophylactic therapy. Cancer Res 65:10145-10148
11. Huber A, Bai P, de Murcia JM et al (2004) Parp-1, PARP-2 and ATM in the DNA damage response: Functional synergy in mouse development. DNA Repair (Amst) 3:1103-1108
12. Martin-Oliva D, Aguilar-Quesada R, O'Valle F et al (2006) Inhibition of poly(ADP-ribose) polymerase modulates tumor-related gene expression, including hypoxia-inducible factor-1 activation, during skin carcinogenesis. Cancer Res 66:5744-5756
13. Pouyssegur J, Dayan F, Mazure NM (2006) Hypoxia signalling in cancer and approaches to enforce tumour regression. Nature 441:437-443
14. Woon EC, Threadgill MD (2005) Poly(ADP-ribose)polymerase inhibition - where now? Curr Med Chem 12:2373-2392
15. Durkacz BW, Irwin J, Shall S (1981) Inhibition of (ADP-ribose)n biosynthesis retards DNA repair but does not inhibit DNA repair synthesis. Biochem Biophys Res Commun 101:1433-1441
16. Rankin PW, Jacobson EL, Benjamin RC et al (1989) Quantitative studies of inhibitors of ADP-ribosylation in vitro and in vivo. J Biol Chem 264:4312-4317
17. Southan GJ, Szabo C (2003) Poly(ADP-ribose) polymerase inhibitors. Curr Med Chem 10:321-340
18. Beneke S, Diefenbach J, Burkle A (2004) Poly(ADP-ribosyl)ation inhibitors: Promising drug candidates for a wide variety of pathophysiologic conditions. Int J Cancer 111:813-818
19. Lunec J, George AM, Hedges M et al (1984) Post-irradiation sensitization with the ADP-ribosyl-transferase inhibitor 3-acetamidobenzamide. Br J Cancer Suppl 6:19-25
20. Bernstein C, Bernstein H, Payne CM et al (2002) DNA repair/pro-apoptotic dual-role proteins in five major DNA repair pathways: Fail-safe protection against carcinogenesis. Mutat Res 511:145-178
21. Schreiber V, Ame JC, Dolle P et al (2002) Poly(ADP-ribose) polymerase-2 (PARP-2) is required for efficient base excision DNA repair in association with PARP-1 and XRCC1. J Biol Chem 277:23028-23036
22. Curtin NJ (2005) PARP inhibitors for cancer therapy. Expert Rev Mol Med 7:1-20
23. Calabrese CR, Almassy R, Barton S et al (2004) Anticancer chemosensitization and radiosensitization by the novel poly(ADP-ribose) polymerase-1 inhibitor AG14361. J Natl Cancer Inst 96:56-67
24. Chalmers A, Johnston P, Woodcock M et al (2004) Parp-1, PARP-2, and the cellular response to low doses of ionizing radiation. Int J Radiat Oncol Biol Phys 58:410-419
25. Noel G, Godon C, Fernet M et al (2006) Radiosensitization by the poly(ADP-ribose) polymerase inhibitor 4-amino-1,8-naphthalimide is specific of the s phase of the cell cycle and involves arrest of DNA synthesis. Mol Cancer Ther 5:564-574
26. Veuger SJ, Curtin NJ, Richardson CJ et al (2003) Radiosensitization and DNA repair inhibition by the combined use of novel inhibitors of DNA-dependent protein kinase and poly(ADP-ribose) polymerase-1. Cancer Res 63:6008-6015
27. Boulton S, Kyle S, Durkacz BW (1999) Interactive effects of inhibitors of poly(ADP-ribose) polymerase and DNA-dependent protein kinase on cellular responses to DNA damage. Carcinogenesis 20:199-203
28. Farmer H, McCabe N, Lord CJ et al (2005) Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434:917-921
29. Bryant HE, Schultz N, Thomas HD et al (2005) Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 434:913-917
30. Gallmeier E, Kern SE (2005) Absence of specific cell killing of the BRCA2-deficient human cancer cell line CAPAN1 by poly(ADP-ribose) polymerase inhibition. Cancer Biol Ther 4:703-706
31. McCabe N, Lord CJ, Tutt AN et al (2005) BRCA2-deficient CAPAN-1 cells are extremely sensitive to the inhibition of poly (ADP-ribose) polymerase: An issue of potency. Cancer Biol Ther 4:934-936
32. Edwards SL, Brough R, Lord CJ et al (2008) Resistance to therapy caused by intragenic deletion in BRCA2. Nature 451:1111-1115
33. Turner NC, Lord CJ, Iorns E et al (2008) A synthetic lethal SIRNA screen identifying genes mediating sensitivity to a PARP inhibitor. Embo J 27:1368-1377
34. Jagtap PG, Baloglu E, Southan GJ et al (2005) Discovery of potent poly(ADP-ribose) polymerase-1 inhibitors from the modification of indeno[1,2-c]isoquinolinone. J Med Chem 48:5100-5103
35. Perkins E, Sun D, Nguyen A et al (2001) Novel inhibitors of poly(ADP-ribose) polymerase/PARP1 and PARP2 identified using a cell-based screen in yeast. Cancer Res 61:4175-4183
36. Oliver AW, Ame JC, Roe SM et al (2004) Crystal structure of the catalytic fragment of murine poly(ADP-ribose) polymerase-2. Nucleic Acids Res 32:456-464
37. Tentori L, Leonetti C, Scarsella M et al (2003) Systemic administration of GPI 15427, a novel poly(ADP-ribose) polymerase-1 inhibitor, increases the antitumor activity of temozolomide against intracranial melanoma, glioma, lymphoma. Clin Cancer Res 9:5370-5379
38. Plummer ER (2006) Inhibition of poly(ADP-ribose) polymerase in cancer. Curr Opin Pharmacol 6:364-368